High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity

Radiotherapy and Oncology

Volumn 110, Issue 2, 2014, Pages 268-271

  Hoskin, Peter ^a   Rojas, Ana ^a   Ostler, Peter ^a   Hughes, Robert ^a   Alonzi, Roberto ^a   Lowe, Gerry ^a   Bryant, Linda ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Early adverse events; High dose rate brachytherapy; Large dose per fraction; Monotherapy; Prostate cancer; Single dose

Indexed keywords

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; DISEASE SEVERITY; DOSIMETRY; GASTROINTESTINAL SYMPTOM; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; SCORING SYSTEM; URINARY TRACT DISEASE; GASTROINTESTINAL DISEASES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION RESPONSE; RECTUM; URETHRA; UROLOGIC DISEASES;

IRIDIUM;

AGED; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; GASTROINTESTINAL DISEASES; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION INJURIES; RECTUM; URETHRA; UROLOGIC DISEASES;

EID: 84896398576     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.09.025     Document Type: Article

References (19)

1. M. Ghilezan, A. Martinez, G. Gustason, D. Krauss, J.V. Antonucci, and P. Chen et al. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data Int J Radiat Oncol Biol Phys 83 2012 927 932
2. C. Corner, A.M. Rojas, L. Bryant, P. Ostler, and P. Hoskin A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 441 446
3. D.J. Demanes, A.A. Martinez, M. Ghilezan, D.R. Hill, L. Schour, and D. Brandt et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer Int J Radiat Oncol Biol Phys 81 2011 1286 1292
4. P. Hoskin, A. Rojas, G. Lowe, L. Bryant, P. Ostler, and R. Hughes et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence Int J Radiat Oncol Biol Phys 82 2012 1376 1384
5. A.A. Martinez, J. Demanes, C. Vargas, L. Schour, M. Ghilezan, and G.S. Gustafson High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer Am J Clin Oncol 33 2010 481 488
6. E.C. White, M.R. Kamrava, J. Demarco, S.J. Park, P.C. Wang, and O. Kayode et al. High-dose-rate prostate brachytherapy consistently results in high quality dosimetry Int J Radiat Oncol Biol Phys 85 2013 543 548
7. Y. Yoshioka, K. Konishi, I. Sumida, Y. Takahashi, F. Isohashi, and T. Ogata et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions Int J Radiat Oncol Biol Phys 80 2011 469 475
8. P.J. Hoskin, A. Colombo, A. Henry, P. Niehoff, T. Paulsen Hellebust, and F.A. Siebert et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update Radiother Oncol 197 2013 325 332
9. T. Simnor, S. Li, G. Lowe, P. Ostler, L. Bryant, and C. Chapman et al. Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer Radiother Oncol 93 2009 253 258
10. M. Barkati, S.G. Williams, F. Foroudi, K.H. Tai, S. Chander, and S. van Dyk et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial Int J Radiat Oncol Biol Phys 82 2012 1889 1896
11. P. Ghadjar, T. Keller, C.A. Rentsch, B. Isaak, F. Behrensmeier, and A. Stroux et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy Brachytherapy 8 2009 45 51
12. P.J. Prada, I. Jimenez, H. Gonzalez-Suarez, J. Fernandez, C. Cuervo-Arango, and L. Mendez High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results Brachytherapy 11 2012 105 110
13. Y. Yoshioka, K. Konishi, R.J. Oh, I. Sumida, H. Yamazaki, and S. Nakamura et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer Radiother Oncol 80 2006 62 68 (Pubitemid 44226435)
14. N. Zamboglou, N. Tselis, D. Baltas, T. Buhleier, T. Martin, and N. Milickovic et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results Int J Radiat Oncol Biol Phys 85 2012 672 678
15. B.J. Davis, E.M. Horwitz, W.R. Lee, J.M. Crook, R.G. Stock, and G.S. Merrick et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy Brachytherapy 11 2012 6 19
16. C. Salembier, P. Lavagnini, P. Nickers, P. Mangili, A. Rijnders, and A. Polo et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy Radiother Oncol 83 2007 3 10 (Pubitemid 46527942)
17. A. Gomez-Iturriaga Pina, J. Crook, J. Borg, and C. Ma Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) >/=180 Gy Int J Radiat Oncol Biol Phys 78 2010 422 427
18. M.A. Kollmeier, R.G. Stock, and N. Stone Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality Int J Radiat Oncol Biol Phys 57 2003 645 653 (Pubitemid 37194290)
19. R.G. Stock, N.N. Stone, A. Tabert, C. Iannuzzi, and J.K. DeWyngaert A dose-response study for I-125 prostate implants Int J Radiat Oncol Biol Phys 41 1998 101 108 (Pubitemid 28211308)